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Abstract. To determine the effect of chloroquine chemoprophylaxis during pregnancy 
on birth weights, a randomized trial was carried out in 1987 and 1988 in Banfora, Burkina 
Faso (West Africa). Seven hundred forty-five randomly selected women treated with chlo- 
roquine sulfate were compared to with 7 19 controls who received no treatment. In spite 
of an unquestionable effect of chloroquine in preventing placental infection (4.1 % infected 
placentas in the treated group versus 19.0% in the controls), the mean difference in birth 
weights between the two groups (6 g) was not significant. The difference in the proportion 
of low birth weight (LBW) newborn babies in two groups (1 6.3% versus 16.4%) was also 
not significant. However, there was a strong relationship between placental infection and 
birth weight (the mean birth weight difference between infected and uninfected placentas 
was I 13 g, and the proportion of LBW babies was 26.0% in infected placentas versus 14.8% 
in uninfected placentas). The small difference in birth weights observed between the two 
groups may be due to the fact that the prevalence rate of placental infection is low and 
that prophylaxis is effective only on a portion of the subjects in the treated group. It may 
also indicate that malaria is only one of several risk factors responsible for LBW. The 
relatively small increase in birth weight, the expected poor acceptance of mass prophylaxis, 
and the spreading of chloroquine-resistant Plasmodium strains should be considered before 
extending malaria chemoprophylaxis to all pregnant women. It might be worth considering 
to limit prophylaxis to primigravidae. 
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One of the main consequences of malaria in 
pregnant women that have been described in sub- 
Saharan Africa is low birth weight among babies 
bom to mothers whose placentas were infected. I -  
I I  This is one of the reasons that motivated the 
World Health Organization (WHO) in 1984 to 
recommend chemoprophylaxis with chloroquine 
during pregnancy. By lowering the rate of ma- 
ternal and thus placental infection, one can ex- 
pect that such a prbphylaxis would both increase 
mean birth weights of the babies bom to treated 
mothers and improve child survival. Although 
the necessity to evaluate the precise effect of ma- 
ternal malaria on birth weight has been frequent- 
ly stressed,12 no carefully controlled trial of chlo- 
roquine prophylaxis has been reported. 
In Burkina Faso (West Africa), since chemo- 
prophylaxis was not believed to produce a sig- 
nificant reduction in morbidity and mortality,I3 
the only recommendation of the Ministry of 
Health was chloroquine treatment of febrile ep- 
isodes. This made it possible to perform a ran- 
domized trial in 1987 and 1988 on the impact 
of chloroquine prophylaxis during pregnancy in 
the city of Banfora. 
MATERIALS AND METHODS 
Study site 
Banfora is a city of 35,000 inhabitants located 
in the southwestem part of Burkina Faso. Ma- 
laria is hyperendemic, with seasonal transmis- 
sion strongly influenced by rainfall. At the time 
of the study, there were a Maternal and Child 
Health (MCH) center and a matemity ward as- 
sociated with the province hospital in Banfora. 
Strong support was given to the MCH center by 
the provincial health department (education of 
pregnant women, vaccination campaigns, etc.) 
and the staff was highly motivated. As a result, 
approximately 80% of the pregnant women liv- 
ing in the city attended the prenatal center at 
least once before delivery. As noted above, che- .’ 
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moprophylaxis with chloroquine was not rec- 
ommended by the Ministry of Health, and a pre- 
liminary study established that self-administered 
chemoprophylaxis was rare among pregnant 
women. 
Study design 
Between February 1987 and February 1988, 
every pregnant woman attending the MCH cen- 
ter was included in the study. At the first visit 
(before the fifth month of pregnancy for the ma- 
jority of the women), information on ethnicity 
and parity was recorded. Two local investigators 
and a supervisor were hired and trained in Bobo- 
Dioulasso, Burkina Faso, then relocated to Ban- 
fora, where they were in charge of the followup. 
They explained the principles of the trial to the 
women, and those willing to participate gave their 
verbal consent and were included in the study. 
For the sake of simplicity, an alternate allocation 
of treatment was performed, in which the women 
were divided into two groups (treated and con- 
trol). Women in the treated group were given 
300 mg of chloroquine sulfate (Nivaquine Forte; 
Specia Laboratories; Rhone-Poulene Sante, Par- 
is, France) once a week, as recommended by the 
WHO. For technical reasons, it was not possible 
to give a placebo to women in the control group. 
On each visit (once a week at the patient’s home) 
.until delivery, information about the health of 
the woman and the intake of drugs since the last 
visit was collected. A blood film and a fingerprick 
sample for serologic studies were collected every 
two weeks. The oral intake of chloroquine by 
women in the treated group was supervised by 
the investigator at the time of the domiciliary 
visit. 
At the time of delivery, information on the 
newborn baby (particularly clinical status and 
birth weight) and anthropometric indices of the 
mother (weight, size, triceps skinfold, etc.) were 
recorded. Samples from maternal and cord blood 
and from placenta were collected for serologic 
analysis and examined for malaria parasites. 
Samples were identified with a number, stained, 
refrigerated as needed, and sent.flwice a week to 
the ORSTOM laboratory in Bobo-Dioulasso, 
where slide examination and serologic assays were 
carried out. Thick and thin blood films and pla- 
cental smears were stained with Giemsa. At least 
200 fields were examined for malaria parasites 
before a slide was considered negative. More than 
95% of the identified parasites were Plasmodiuni 
falciparum. Laboratory technicians had no in- 
formation on the status of the individuals from 
whom the samples had been taken, as did the 
midwives who weighed the newborn babies. One 
of the two principal investigators (M. C. or A. 
R.) visited the study area at least twice a week. 
To ensure both the quality of data collection 
and adherence to the study design, additional 
investigations were performed three times on 20 
randomly chosen women. Questionnaire data 
were checked and urine samples were tested for 
the presence of amino quinolines using the Has- 
kins test.14. l 5  During the main investigation, re- 
sistance to chloroquine was spreading in West 
Africa. After the study was terminated, an in- 
vestigation on in vivo sensitivity to chloroquine 
of P. falciparum isolated from a sequential sam- 
ple of pregnant women attending the MCH cen- 
ter was carried out.I6 
Statistical analysis 
Differences in proportions were tested using 
Pearson’s chi-square test. The Armitage test was 
used to evaluate trends in relative risk (RR) es- 
timates.” The RR confidence limits were cal- 
culated according to the formula of Greenland 
and Robins. Differences between means were 
tested using the Student’s t-test. 
RESULTS 
Description of the populations 
One thousand five hundred forty women were 
enrolled in the study (Figure 1). Seventy-six of 
these were studied separately; 24 had started a 
prophylaxis by themselves before the first visit 
to the MCH center (volunteer group), and 52 
refused to participate (refusal group). The re- 
maining 1, 464 women were divided into two 
groups: 745 treated (weekly prophylaxis) and 7 19 
controls (no prophylaxis). At the beginning of 
the investigation, one of the investigators incor- 
rectly classified women willing to take a prophy- 
laxis (but not having initiated it) in the volunteer 
group instead of in the treated group. These 
women were reassigned to the treated group a 
few days later; this explains the disproportion in 
numbers observed between the treated and con- 
trol groups. 
There were slightly more exclusions from the 
!cm 
in- 
3m 
the 
h e  
A. 
:k. 
ion 
na1 
20 
ata 
for 
as- 
re- 
est 
in- 
ine 
m- 
:n- 
ing 
vas 
es- 
:al- 
.nd 
ere 
ere 
Y of 
:d a 
risit 
52 
re- 
two 
719 
; of 
:or- 
teer 
lese 
P a  
n in 
on- 
Ihy- 
the 
i 
CHLOROQUINE PROPHYLAXIS DURING PREGNANCY 
Total number at subjects TABLE 1
Characteristics of the treated and control groups in this 
study 
Treated Controls 
77 Total : 76 I 24 52  Volunleers Ref sal 
No. (%) No. (%I Characteristic 
Treated Control Age (years) 
126 (17.1) 
20-24 216 (29.4) 
' 25-30 191 (26.0) f 
Delivery 
OUI of lhe 
malernlty 
Total : 122 
f 
Delivery 
out of the 
maternlty 
Tolal : 141 
f 
slill birlhs (13) 
Aborlions (6) 
Tolal : 19 
Q pregnancies Tolal : i 0  
23 
i I SII11 birlhs (11) 
Aborllons (5) ' 
Total : 16 
Multiple 
pregnancies I' Tolal : 8 
Collected placentae 
.' B 
FIGURE 1. Composition of the subject and control 
populations in the randomized trial of chloroquine 
prophylaxis during pregnancy in Banfora, Burkina Faso 
(1987- 1988). 
control group than from the treated group be- 
tween the beginning of the study and the time of 
delivery. Most of these exclusions represented 
women who delivered outside the hospital (1 4 1 
in the control group and 122 in the treated group); 
the larger number of exclusions in the control 
group may be due to better motivation in the 
women receiving prophylaxis. Other reasons for 
exclusion (abortions, still births, multiple preg- 
nancies) were equally distributed between the two 
groups (29 and 24, respectively). Overall, 594 in 
the treated group and 554 in the control group 
could be followed until the end oftheir pregnancy 
and gave birth to a live child. 
Characteristics of ìreated and control subjects 
As shown in Table 1, the treated and control 
groups were comparable for age, parity, district 
of habitation, ethnic group, duration of followup, 
and nutritional status (mean value of weight-for- 
height index or Quetelet's index = 22.0 for the 
treated group and 22.2 for the control group, not 
significant). 
Compliance with treatment 
Fifteen women from the treated group re- 
ceived no prophylaxis. They were either lost to 
30-35 119 (16.2j 
>35 83 (11.3) 
1 106 (14.4) 
2-3 239 (32.6) 
4-5 178 (24.3) 
>5 211 (28.7) 
Central 384 (52.3) 
Peripheral 350 (47.7) 
Gestation rank 
District 
Ethnic group 
Bobo 35 (4.9) 
Dioula 78 (11.0) 
Dagan 32 (4.5) 
Mossi 130 (18.4) 
Peul 44 (6.2) 
Senoufo 307 (43.4) 
Sam0 37 (5.2) 
Other 45 (6.4) 
< 2  145 (21.6) 
2-3 143 (21.3) 
3-4 151 (22.5) 
4-5 108 (16.1) 
> 5  125 (18.6) 
Duration of followup (months) 
114 
220 
185 
107 
85 
113 
212 
182 
204 
38 1 
328 
47 
80 
34 
132 
46 
288 
35 
22 
125 
132 
130 
139 
106 
(16.1) 
(30.9) 
(26.0) 
(15.0) 
(1 2.0) 
(15.9) 
(29.8) 
(25.6) 
(28.7) 
(53.6) 
(46.4) 
(6.9) 
(5.0) 
(6.7) 
(5.1) 
(3.2) 
(1 1.7) 
(19.3) 
(40.7) 
(19.8) 
(20.9) 
(20.6) 
(22) 
(1 6.8) 
followup or delivered within a week after the first 
visit to the MCH center. Sixty-four women from 
the control group'were treated with antimalarial 
drugs during their pregnancies. At the first ex- 
amination, two women had a strongly positive 
Haskins test result associated with the admin- 
istration of chloroquine by one of the local in- 
vestigators. Subsequent examinations detected 
no additional incorrect classifications by the in- 
vestigator~.'~ The remaining 62 women inde- 
pendently took a short treatment since they be- 
lieved they had malaria. 
Addit ional in vest igatio n 
Evaluation of the in vivo sensitivity of P. fal- 
ciparum to chloroquine showed that none of the 
36 women tested carried a resistant strain, in- 
dicating a therapy success rate of > 990/o.16 
, 
TABLE 2 
Proportion of infected placentae by duration of prophy- 
laxis 
~~ 
Duration of 
treatment Infected 
(weeks) placenta 
Control 83 
Treated (weeks) 
<4 5 
4-7 4 
8-1 1 4 
> 12 6 
TotaI treated 19 
Unin- 
feeted 
placenta 
354 
41 
57 
118 
228 
444 
Relative risk* 
1 .o 
0.57 (0.24-1.34) 
0.35 (0.1 3-0.9 1) 
O. 17 (0.06-0.46) 
0.14 (0.06-0.30) 
0.22 (0.13-0.35) 
* Values in parentheses are 95% confidence intervals. Armitage test for 
trend to duration of prophylaxis: xZT = 62.52; 1 degree of freedom; P < 
10-6. 
Effect of prophylaxis on placental infection 
Nine hundred four placentas were collected 
and examined from the 1 , 148 women in whom 
followup was possible. Data on chemoprophy- 
laxis were incomplete for four women, who have 
not been included in the analysis. The relative 
risk of placental infection in the treated group 
decreased with increasing duration of prophy- 
laxis (Table 2) when compared with those in the 
control group. The RR of placental infection was 
0.57 when the duration of prophylaxis was less 
than one month, and it decreased significantly 
(0.35, 0.17, and 0.14 over one-month periods) 
when the duration ofprophylaxis increased. There 
was a significant linear trend of decreased infec- 
tion with the duration of prophylaxis (Armitage 
test for trend xzT = 62.52; 1 degree of freedom 
[dfl; P < 
Thus, it can be concluded that prophylaxis is 
not effective when administered for less than one 
month. Fourteen women who received chloro- 
quine for more than one month had a placental 
infection. Six of them had taken it irregularly or 
had stopped the treatment at Ieast two weeks 
before delivery. The eight remaining women had 
been taking their treatment correctly, but the pla- 
centas showed low parasite densities (usually 
< 1 O0 parasitedm1 of blood). 
, 
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Conzparison of birth weights in the treated and 
control groups 
This comparison was performed in the 1 , 148 
women who were followed until the end of their 
pregnancies (Figure 1). The average difference 
between birth weights in the two groups was 5.6 
g (P not significant) (Table 3). The relative risk 
of having a low birth weight (< 2, 500 g) for a 
newborn child was not decreased by prophylaxis 
(RR = 0.99, 95% confidence intervals [CI] = 
0.76-1.29, x2 = 0.003; df = 1, not significant) 
(Table 4). 
Since the primigravidae appear to be a high- 
risk group for low birth weight (LBW), birth 
weight comparisons were also performed in the 
treated (n = 106) and untreated (n = 113) nul- 
liparae. The average difference in birth weight 
was 82 g (P = 0.25; not significant) and the rel- 
ative risk of having an LBW was 0.88 (95% CI 
= 0.64-1.21, x2 = 0.64; df = 1, not significant). 
Relationship between placental infection and birth 
weight 
Placentas were collected from 904 ofthe I , 148 
followed women (Figure 1). Mean birth weights 
were higher among children whose mothers had 
uninfected placentas (difference of 113 g; P < 
0.02) (Table 5), and the relative risk of having 
an LBW for a newborn baby was increased by 
placental infection (RR = 1.76, 95% CI = 1.22- 
2.54, xz = 8.59; df = 1; P < 0.005) (Table 6). 
DISCUSSION 
The randomized trial performed in Banfora 
confirmed the association between placental in: 
fection and LBW. The administration of chlo- 
roquine during pregnancy proved to be highly 
protective against infection of the placenta with 
malaria parasites. However, the difference in 
mean birth weight between the treated and con- 
TABLE 3 
Relationship of mean birth weight (in grams) lo inclusion status (treated or control) 
Treated Control Dilference' 
Mean value 2,937.8 2,932.2 5.6 (-46.8-58) 
Standard error of the mean 452.5 467.4 
Number of subjects 594 554 
* Values in parentheses are 95% confidence intcrvals. 
I-test value = 0.2; 1 ,  146 degrces of frecdom; noi significant. 
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TABLE 4 
Proportion of low birth weights (less than 2,500 g) by inclusion status (treated or control) 
25 
- 
Treated Control 
No. (W No. (%I Relative risk’ 
Birth weight, ~2,500 g 97 (16.3) 91 (1 6.4) 0.99 (0.76-1.29) 
Birth weight, >2,500 g 498 463 
* Values in parentheses are 95% confidence intervals. 
2 = 0.003; 1 degree of freedom; not significant. 
trol groups was very small and not statistically 
significant. ’ 
These results may be explained in two ways. 
First, the prevalence of placental malaria was 
relatively low (1 9%) among the untreated wom- 
en. With a mean 113-g deficit in birth weight 
attributable to placental malaria, the overall ex- 
pected effect of prophylaxis in the treated group 
would be 1 13 x O. 19 or 2 1.5 dpregnancy. In the 
sample we studied, the observed difference be- 
tween the two groups should have been greater 
than 50 g to be statistically significant. Such a 
difference would have led to the conclusion of a 
direct effect of malaria on birth weight, but would 
this difference be sufficient to justify a general- 
ized mass prophylaxis? Since primigravidae are 
known to be a high-risk group for both malaria 
and LBWY2.-’. * we compared birth weights in this 
subset of women. The difference between the 
treatment groups was higher than in the overall 
population (82 g), but was not statistically sig- 
nificant. Such an absence of a difference can be 
attributed to the small sample size, and we would 
expect a higher effectiveness of the prophylaxis 
when given only to primigravidae, as suggested 
in a recent study in Gambia.I9 
Second, malaria is associated with other fac- 
tors (nutritional status, ethnic origin, duration of 
pregnancy, etc.) that are known to cause LBW, 
and its relative importance may not be as high 
as generally believed. The 6 g difference in birth 
weight observed between the treated and control 
groups is lower than the expected difference of 
21.5 g, which suggests that malaria is not the 
only relevant factor. An ongoing multivariate 
analysis will attempt to evaluate the role of ma- 
laria when other risk factors are taken into ac- 
count. 
Two potential sources of bias could be ‘iden- 
tified in this study. First, some women were er- 
roneously classified in the volunteer group at the 
beginning of the trial. They should have been 
excluded from the study, and not reclassified in 
the treated group a few days later. Unfortunately, 
these subjects were not clearly identified, and it 
was impossible to exclude them afterwards. Since 
their number was relatively small (approximate- 
ly 20 subjects), and a comparison of the treated 
and control subjects showed no difference be- 
tween the two groups, this misclassification is 
unlikely to have been a major source of bias. 
Second, the loss of contact with subjects during 
the followup was more prevalent in the control 
group than in the treated one (141 versus 122). 
This difference was due mainly to women who 
delivered at home. We performed another com- 
parison between the two groups at the end of the 
followup, which showed no statistical differences 
for age, parity, district of habitation, ethnic group, 
and nutritional status. It is, therefore, unlikely 
that bias resulting from the loss of followup had 
any appreciable effect on our results. 
To our knowledge, two studies have been per- 
formed on the effect of antimalarial prophylaxis 
on the course and outcome of pregnancy. In 1972, 
McGregor and Avery’O demonstrated in the So- 
lomon islands an important increase in birth 
weight associated with a decrease in malarial 
TABLE 5 
Relationship of wean birth weight (in grams) to placental infection 
Infected placenta Uninfected placenta Difference* 
~~ ~~ 
2,842.2 2,955.2 113 (9.54-216.45) Mean value 
Standard error of the mean 513.2 450.4 
Number of subjects 104 800 
*Values in parentheses are 95% confidence intervals. 
Hest value = 2.37; 902 degrees of freedom; P < 0.02. 
TABLE 6 
Proportion of low birth weights (less than 2,500 g) by placenta infection 
Infected placenta Uninfected placenta 
Relative risk* No. (W No. (%I 
(14.8) 1.76 (1.22-2.54) Birth weight, <2,500 g 27 (26.0) 118 
Birth weight, >2,500 g 77 682 
* Values in parentheses are 95% confidence intervals. 
x* = 8.59; I degree of freedom; P < 0.005. 
prevalence after an insecticide spraying cam- 
paign. Placental infection rates were not record- 
ed, but the prevalence of malarial infection in 
the 2-9-year-old age group before spraying was 
29.7%, and decreased to 12.8% after spraying. 
The increase in mean birth weight was 165 g, 
and there was a corresponding decrease in the 
LBW rate from 20.5% to 11.8%. This study was 
discussed by =amer'2 who estimated that given 
a placental infection rate of 40% and a 170-g 
deficit among women with placental malaria, the 
attributable impact of malaria would be 170 X 
0.40 = 68 &pregnancy, which is much lower than 
the 165-g decrease estimated by McGregor and 
Avery. This indicates that other factors may have 
played a role in the difference observed in this 
study. Since the two groups in this study were 
not strictly comparable (the study design was a 
comparison of the same population with a two- 
year interval, and not a randomized trial), the 
conclusions made by the investigators should be 
viewed with caution. In our randomized trial, 
the observed placental infection rate was 19%, 
and as mentioned above, the expected attribut- 
able impact of malaria on birth weight was mod- 
erate (21.5 g), which seems a more reasonable 
estimate with respect to the analysis of Kramer. 
More recently, Greenwood and others studied 
the efficacy of a pyrimethamine prophylaxis giv- 
en by traditional birth attendants in Gambia.I9 
Placental prevalences were not recorded, but the 
investigators reported a marked effect of pro- 
phylaxis on birth weight in primigravidae; there 
was no significant effect on the overall popula- 
tion. 
In conclusion, since the causal impact of ma- 
lana on birth weight is uncertain, the prevalence 
of placental malaria is low in many areas, the 
compliance to a generalized prophylaxis pro- 
gram is generally poor,2o and there is a rapid 
spreading of chloroquine-resistant P. faleiparurn 
throughout Africa, the effect of an extension of 
chloroquine prophylaxis to all pregnant women 
might be disappointing in terms of birth weight 
improvement. However, a policy of giving che- 
moprophylaxis only to primigravidae might be 
recommendable, provided that the administra- 
tion of antimalarial drugs during a first pregnan- 
cy does not increase susceptibility to malaria 
during the second pregnan~y.~. l9 This question 
is being investigated in Cameroon, where we are 
following the second pregnancies of women pro- 
tected with chloroquine during their first preg- 
nancy. 
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